» 
The CTA is Submitted
Copy URL
https://www.pharmnovo.com/post/the-clinical-trial-application-cta-has-been-submitted

The CTA is Submitted

May 30, 2022

PharmNovo is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as to the ethics committee for a phase I First in Human (FIH) clinical trial with our lead candidate PN6047.

The FIH trial will be conducted at the Swedish CRO Clinical Trial Consultants AB (CTC) at their FIH facility in Uppsala. It is planned to enrol approximately 100 healthy subjects into the trial.

The CTA submission is the culmination of several years of dedicated CMC- and preclinical work creating documentation that the compound is safe for human testing, and the submission of the CTA for the FIH clinical trial represent a major milestone in the development of PN6047.

Petra Larson
Author:
Petra Larson
Copy URL
https://www.pharmnovo.com/post/the-clinical-trial-application-cta-has-been-submitted

The CTA is Submitted

May 30, 2022

PharmNovo is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as to the ethics committee for a phase I First in Human (FIH) clinical trial with our lead candidate PN6047.

The FIH trial will be conducted at the Swedish CRO Clinical Trial Consultants AB (CTC) at their FIH facility in Uppsala. It is planned to enrol approximately 100 healthy subjects into the trial.

The CTA submission is the culmination of several years of dedicated CMC- and preclinical work creating documentation that the compound is safe for human testing, and the submission of the CTA for the FIH clinical trial represent a major milestone in the development of PN6047.

Petra Larson
Author:
Petra Larson

Latest news

View all
May 2, 2023

PharmNovo attending LSX 3–4 May

PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.

Read more
May 2, 2023

Jesper Kjerulff leads again

PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.

Read more
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

OK